Cite

HARVARD Citation

    McCoach, C. et al. (2021). Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET‐Positive Non‐Small‐Cell Lung Cancer. JCO precision oncology. p. . [Online]. 
  
Back to record